However, given that multiple MEK inhibitors are already approved for clinical use with long-term data supporting their safety (56, 65, 70, 100), we propose that MEK inhibition could represent a viable therapeutic strategy for both inherited and acquired blistering diseases and disorders of cornification, all of which are in great need of novel treatments. The gene discussed is MAP2K7; the disease is ichthyosis.